Ectopic pregnancy statistics: how common it is, how it is treated, and who dies

She was six weeks from her last period and had already been told, twice, that the pregnancy was "too early to see." The third visit, she arrived pale, with shoulder pain she kept dismissing as a pulled muscle from lifting her toddler. On ultrasound there was free fluid in the cul-de-sac and no intrauterine sac. By the time the OR team was ready she needed two units of blood. The tube was ruptured. She lived. Not every patient in that position does.

Ectopic pregnancy is not rare, and it is not a historical problem. According to CDC summaries, roughly 1% to 2% of pregnancies in the United States are ectopic. That small share has long accounted for about 3% to 4% of pregnancy-related deaths. Outpatient methotrexate means many cases never appear in hospital discharge data, so national incidence has been harder to pin down since the early 1990s. Every figure below is tied to a named source a reporter or clinician can open and cite.

Year / period	Rate per 1,000 pregnancies
1970	4.5
1987	16.8
1989	16.0
1992	19.7

Source: CDC MMWR ectopic pregnancy surveillance (1970-1987; 1970-1989; 1990-1992 combined inpatient and outpatient estimate for 1992).

Measure	Value	Source
Methotrexate share, 2006	14.5%	Hsu et al., AJOG 2017 (U.S. hospital database, n=62,588)
Methotrexate share, 2015	27.3%	Hsu et al., AJOG 2017
Surgical treatment overall, 2006-2015	78.4%	Hsu et al., AJOG 2017
Salpingostomy among surgical cases, 2006	13.0%	Hsu et al., AJOG 2017
Salpingostomy among surgical cases, 2015	6.0%	Hsu et al., AJOG 2017
Methotrexate failure (commercial claims, 2002-2007)	14.7%	Hoover et al., Obstet Gynecol 2010

Source: Hsu et al., American Journal of Obstetrics & Gynecology, 2017; Hoover et al., Obstetrics & Gynecology, 2010.

How common is ectopic pregnancy

The number everyone quotes is also the number with the weakest modern surveillance. CDC and clinical reviews state that approximately 1% to 2% of pregnancies in the United States are ectopic. That range is how public-health summaries translate the last full national measurement and later claims work. It is not a soft estimate invented for handouts.

In 1992, the CDC combined inpatient National Hospital Discharge Survey data with outpatient National Hospital Ambulatory Medical Care Survey data and estimated 108,800 ectopic pregnancies, a rate of 19.7 per 1,000 reported pregnancies (about 2%). That report also noted that ectopic pregnancy-related deaths accounted for 9% of all pregnancy-related deaths that year. Hospitalization-only counts for the same period were much lower (about 10-11 per 1,000 pregnancies), as expected once outpatient diagnosis and methotrexate expanded.

After the early 1990s, the United States stopped producing a single authoritative annual rate. Hoover and colleagues analyzed more than 200 commercial health plans from 2002 to 2007 and found an overall rate of 0.64% among pregnant women aged 15-44, with no clear trend. The rate rose with age: 0.3% at ages 15-19 and 1.0% at ages 35-44. Medicaid looks different. Stulberg and colleagues reported rates of 2.38% of pregnancies in New York, 2.07% in California, and 2.43% in Illinois among Medicaid beneficiaries in 2000-2003. In a later 14-state Medicaid analysis for 2004-2008, the combined rate was 1.40% of pregnancies (1.47% age-adjusted), or 2.3 per 1,000 woman-years.

Emergency-department surveillance from Mann and colleagues at CDC, using the HCUP Nationwide ED Sample, puts another marker on the board. From 2006 to 2013, the overall ratio of weighted ED visits with an ectopic pregnancy diagnosis was 12.3 per 1,000 live births, rising from 11.0 to 13.7, nearly a 25% increase. Among all pregnancies, the diagnosis rate rose from 7.0 per 1,000 in 2006 to 8.3 in 2010. ED data are not a full incidence census, but they are one of the few national series still moving after CDC stopped full ectopic surveillance.

For a woman presenting with first-trimester bleeding or pain, the pretest probability is far higher than the population rate. ACOG and related sources report prevalence in that symptomatic group as high as 18%. A negative first ultrasound does not close the case when symptoms persist. Families tracking early pregnancy symptoms sometimes use our implantation calculator or late period checker; those tools do not diagnose ectopic pregnancy, and any unilateral pain, shoulder pain, dizziness, or heavy bleeding needs same-day clinical evaluation.

Population / measure	Rate	Period
CDC national (inpatient + outpatient)	19.7 per 1,000 pregnancies (~2%)	1992
Commercially insured pregnancies	0.64%	2002-2007
Medicaid, 14 states	1.40% of pregnancies	2004-2008
Medicaid NY / CA / IL	2.07%-2.43% of pregnancies	2000-2003
ED diagnoses per 1,000 live births	12.3 overall (11.0 → 13.7)	2006-2013
ED diagnoses per 1,000 pregnancies	7.0 → 8.3	2006-2010

Source: CDC MMWR 1995; Hoover et al. 2010; Stulberg et al. 2013 and 2014; Mann et al., Matern Child Health J 2020 (CDC STACKS).

Mortality and why it still kills

Frequency alone does not explain why ectopic pregnancy keeps appearing in maternal mortality reviews. The lethal mechanism is hemorrhage after tubal rupture. When diagnosis is delayed, the window between "stable and outpatient-eligible" and "shock" can be hours, not days.

CDC materials and the Florida Pregnancy-Associated Mortality Review report state the national pattern cleanly: only about 1% to 2% of pregnancies are ectopic, yet these pregnancies account for 3% to 4% of pregnancy-related deaths. A later national analysis for 2011-2013 found that ruptured ectopic pregnancy accounted for 2.7% of pregnancy-related deaths. That figure is widely cited in the American Academy of Family Physicians' 2020 clinical review.

Deaths have fallen. Creanga and colleagues examined national birth and death certificate data from 1980 through 2007 and identified 876 deaths attributed to ectopic pregnancy. The mortality ratio declined 56.6%, from 1.15 deaths per 100,000 live births in 1980-1984 to 0.50 in 2003-2007. Among hospitalized women who died between 1998 and 2007, 70.5% of deaths involved tubal pregnancies; salpingectomy was performed in 80.6% of cases; and hemorrhage, shock, or renal failure accompanied 67.4% of those deaths.

That improvement is real and incomplete. Sensitive pregnancy tests and earlier ultrasound access moved the case-fatality rate down. Laparoscopy and methotrexate helped once diagnosis was made. What they cannot fix is delayed care. Florida's PAMR documented an abrupt spike from 0.6 ectopic deaths per 100,000 live births in 1999-2008 to 2.5 in 2009-2010, associated with illicit drug use and delays seeking care. Those eleven deaths were 10.8% of that state's pregnancy-related deaths in the period. These deaths sit inside the broader problem we map in our review of preventable pregnancy-related deaths. Ectopic pregnancy should be almost entirely preventable with timely diagnosis.

Risk factors that actually matter

Half of women diagnosed with an ectopic pregnancy have no identifiable risk factor. ACOG Practice Bulletin No. 193 and the AAFP review both state that directly. Screening only high-risk patients will miss a large share of cases.

When risk factors are present, they cluster around tubal damage and prior reproductive events. Prior ectopic pregnancy is the strongest clinical predictor. After one, the chance of recurrence is about 10% (odds ratio 3.0; 95% CI 2.1-4.4). After two or more, the risk exceeds 25% (odds ratio 11.17; 95% CI 4.0-29.5), per ACOG. Other established factors include prior pelvic inflammatory disease, documented tubal pathology or surgery, infertility, cigarette smoking, age over 35, and pregnancy with an intrauterine device in place.

IUDs deserve careful reading. The absolute pregnancy rate with a modern IUD is under 1%. When pregnancy does occur with an IUD in place, the share that are ectopic can be as high as 53%, according to studies cited in the AAFP review. That is a conditional probability, not a claim that IUDs cause ectopic pregnancy in the general population. Age shows up in both incidence and mortality: Hoover found rates rising from 0.3% at ages 15-19 to 1.0% at 35-44, and Creanga found women older than 35 had a 3.5 times higher mortality ratio than women younger than 25 during 2003-2007.

Assisted reproduction raises heterotopic pregnancy risk well above the natural background, which ACOG places roughly between 1 in 4,000 and 1 in 30,000 for natural conceptions and as high as about 1 in 100 after IVF in older estimates. Our IVF and infertility statistics page covers broader outcomes. The clinical point here is narrower: a documented intrauterine pregnancy after IVF does not automatically exclude an ectopic twin in the tube.

When diagnosis usually happens

Most ectopic pregnancies declare themselves in the first trimester. Clinical series and reviews commonly place presentation around 6 to 10 weeks of gestation, often with vaginal bleeding, unilateral pelvic pain, or both. Rupture can occur earlier or later; gestational age alone is a weak safety signal.

Diagnosis is a sequence, not a single test. A positive pregnancy test plus symptoms triggers quantitative β-hCG and transvaginal ultrasound. In a desired pregnancy with an initial β-hCG below 1,500 mIU/mL, viable intrauterine pregnancies almost always rise by at least 49% over 48 hours; slower rises raise concern for ectopic pregnancy or early pregnancy loss. The discriminatory zone was long taught as 1,000 to 2,000 mIU/mL; current caution, reflected in AAFP and Society of Radiologists in Ultrasound guidance, allows a level as high as 3,500 mIU/mL when interrupting a potentially desired pregnancy is on the table.

Definitive ultrasound diagnosis is seeing a yolk sac or embryo in the adnexa. Most ectopics never reach that stage. More often, clinicians manage a pregnancy of unknown location with serial β-hCG, repeat ultrasound, and sometimes uterine aspiration to look for chorionic villi. Aspiration that shows villi avoids unnecessary methotrexate. Early pregnancy loss is far more common than ectopic pregnancy (a point we cover in our miscarriage and pregnancy loss statistics), and the presentations overlap. The job is to rule out the diagnosis that can kill before the next appointment. Patients comparing spotting with guides on implantation bleeding versus period bleeding should know that spotting alone is nonspecific. Shoulder-tip pain, syncope, or pain that worsens over hours is a reason to go to the emergency department.

Methotrexate versus surgery

Treatment has two main paths for a confirmed or highly suspected tubal ectopic pregnancy in a stable patient: intramuscular methotrexate or surgery (usually laparoscopic salpingectomy or salpingostomy). Expectant management is reserved for carefully selected, asymptomatic patients with already low and falling β-hCG levels.

Surgery remains the majority pathway in large U.S. samples. Hsu and colleagues examined 62,588 women with tubal ectopic pregnancy in the Perspective hospital database from 2006 to 2015. Overall, 49,090 (78.4%) were treated surgically and 13,498 (21.6%) received methotrexate. Methotrexate use rose from 14.5% in 2006 to 27.3% in 2015. Among surgical cases, tube-conserving salpingostomy fell from 13.0% to 6.0%.

Earlier commercial claims data from Hoover and colleagues show the same direction. Methotrexate treatment increased from 11.1% of cases in 2002 to 35.1% in 2007, with a failure rate of 14.7% over six years. Laparotomy among surgical cases fell from 40.0% to 33.1%. The pattern is consistent: more medical therapy, less open surgery, and a residual methotrexate failure rate near one in seven in real-world claims.

Success of single-dose methotrexate tracks with the starting β-hCG. A systematic review summarized in the AAFP article reported success rates of 98% when initial β-hCG was under 1,000 mIU/mL, 94% at 1,000-1,999, 96% at 2,000-4,999, 85% at 5,000-9,999, and 81% at 10,000 or higher. ACOG notes failure rates of 14.3% or higher when pretreatment hCG exceeds 5,000 mIU/mL. Patient selection is the therapy.

Insurance and race shape which therapy a woman receives. In Hsu's models, Medicaid recipients (adjusted risk ratio 0.92) and uninsured women (adjusted risk ratio 0.87) were less likely to receive methotrexate than commercially insured patients. Among surgical patients, Black women (adjusted risk ratio 0.76) and Hispanic women (adjusted risk ratio 0.80) were less likely than white women to undergo salpingostomy. Teaching hospitals and higher-volume centers used more methotrexate.

A 2025 Ontario cohort (Rosen and colleagues) offers a recent non-U.S. benchmark: among 17,090 tubal ectopic pregnancies, 48.0% received medical management, 51.1% surgery, and 0.8% both on the same day. Methotrexate failure was 15.3%. Future live birth was higher after medical management (51.6% versus 45.1%), with modestly higher recurrence (7.4% versus 6.4%). Patients who want another pregnancy need counseling on recurrence risk and early ultrasound next time. Our ovulation calculator and period calculator can help with cycle timing once β-hCG is non-pregnant; they are not substitutes for early obstetric care after a prior ectopic pregnancy.

Racial disparities in incidence and death

Disparities in ectopic pregnancy are not subtle, and they are not explained by biology alone.

Incidence is higher for Black women in every large U.S. claims analysis that has looked. In Stulberg's 14-state Medicaid study (2004-2008), Black women were more likely than white women to experience an ectopic pregnancy in all 14 states, with a combined relative risk of 1.46 (95% CI 1.45-1.47). In the earlier three-state Medicaid analysis, the Black-white relative risk was 1.26 (95% CI 1.25-1.28). These relative differences apply to a condition that already kills on a short fuse.

Mortality gaps are wider than incidence gaps. Creanga's national analysis for 2003-2007 found the ectopic pregnancy mortality ratio was 6.8 times higher for African American women than for white women. That is one of the starkest race ratios in U.S. obstetric epidemiology. The same paper found a 3.5-fold mortality elevation for women older than 35 compared with those younger than 25. Improvement in overall ectopic mortality since the 1980s did not close the racial gap.

Treatment disparities compound incidence disparities. Hsu's hospital-database work showed Black and Hispanic patients less often received tube-conserving surgery, and publicly insured or uninsured patients less often received methotrexate. Whether that reflects later presentation, hospital quality, or biased clinical decisions cannot be settled from administrative data alone. All three mechanisms are plausible.

These findings sit inside the same architecture of delayed care and coverage gaps described in our reports on women's healthcare access disparities and preeclampsia and pregnancy complications. Systems that make same-day ultrasound or emergency evaluation hard to get will produce exactly the mortality ratios Creanga measured. The United States still lacks a continuous national ectopic pregnancy registry that includes outpatient cases by race. Incidence disparities come mainly from Medicaid claims; mortality disparities from death certificates. Both point the same direction. Waiting for perfect surveillance before acting on a 6.8-fold mortality gap would be a peculiar form of rigor.

Frequently asked questions about ectopic pregnancy statistics

What percentage of pregnancies are ectopic?

About 1% to 2% of pregnancies in the United States are ectopic, according to CDC summaries. The last CDC national estimate that combined inpatient and outpatient care, for 1992, was 19.7 per 1,000 reported pregnancies (about 2%). Later commercial claims studies report lower rates (around 0.64%), while Medicaid analyses often find rates near 1.4% to 2.4% of pregnancies.

How many pregnancy-related deaths are caused by ectopic pregnancy?

Ectopic pregnancies account for roughly 3% to 4% of pregnancy-related deaths in the United States, per CDC materials. Ruptured ectopic pregnancy accounted for 2.7% of pregnancy-related deaths in 2011-2013. The mortality ratio fell from 1.15 to 0.50 deaths per 100,000 live births between 1980-1984 and 2003-2007, according to Creanga and colleagues.

What are the main risk factors for ectopic pregnancy?

Prior ectopic pregnancy is the strongest risk factor: about 10% recurrence after one and more than 25% after two or more, per ACOG. Other factors include pelvic inflammatory disease, tubal surgery or pathology, infertility, smoking, age over 35, and pregnancy with an IUD in place. About half of women with an ectopic pregnancy have no known risk factor, so symptoms still warrant evaluation.

How is ectopic pregnancy usually treated?

In a large U.S. hospital cohort of 62,588 cases from 2006 to 2015, 78.4% were treated surgically and 21.6% with methotrexate. Methotrexate use rose from 14.5% to 27.3% over that decade. Real-world methotrexate failure rates are about 14%-15% in claims and population studies. Surgery is required for rupture, instability, or contraindications to medical therapy.

Are there racial disparities in ectopic pregnancy?

Yes. In 14-state Medicaid data for 2004-2008, Black women had a 1.46 relative risk of ectopic pregnancy compared with white women. The mortality gap is larger: during 2003-2007, the ectopic pregnancy mortality ratio was 6.8 times higher for African American women than for white women, per Creanga et al. Treatment patterns also differ by race and insurance.

When is ectopic pregnancy usually diagnosed?

Most cases present in the first trimester, commonly around 6 to 10 weeks of gestation, with bleeding, pain, or both. Diagnosis relies on serial β-hCG levels and transvaginal ultrasound rather than a single visit. Among women who come to an emergency department with first-trimester bleeding or pain, prevalence has been reported as high as 18%, far above the population rate of 1% to 2%.